NEW YORK (GenomeWeb) – Illumina has received a product approval certificate for clinical use for its MiSeqDx instrument and MiSeqDx Universal kit from South Korea's Ministry of Food and Drug Safety.

The registration allows Illumina to sell its instrument to clinical laboratories in South Korea, and will "accelerate the process for us to get other Illumina clinical products into this market in the future," Jason Kang, Illumina's commercial leader in South Korea, said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.